HC Wainwright & Co. reiterates Buy rating on Enanta Pharma, $20 price target

HC Wainwright & Co. reiterated their Buy rating on Enanta Pharma's stock with a price target of $20.00.The price target implies an upside of 61.0% from the Sep 22 close of $12.42.Key takeaways from the analyst noteStrong Pipeline Potential: Enanta Pharmaceuticals boasts a promising pipeline, partic…